摘要：
探讨血液和尿液白细胞介素17（IL-17）的表达水平对膀胱癌预测的影响。本研究人群为2022年3月至2023年10月在我院诊断的膀胱癌患者纳入为实验组，以我院同时期体检的健康人群纳入为对照组。比较两组患者的血液和尿液IL-17水平进行分析。共纳入实验组患者31例，健康对照组34例。实验组患者的血液和尿液的IL-17均高于健康对照组，差异具有统计学意义（均＜0.05）。此外，当检测血清和尿液样本之间的差异时，发现血清中的差异明显更高。白介素-17是预测膀胱癌疾病发生和进展有效的免疫标记物。

关键词：白介素-17；膀胱癌；标记物；疾病进展

Abstract:
Objective: To explore the impact of the expression levels of interleukin-17 (IL-17) in blood and urine on the prediction of bladder cancer. Methods: The study population consisted of bladder cancer patients diagnosed at our hospital between March 2022 and October 2023, included as the experimental group, and a healthy control group consisting of individuals undergoing physical examinations during the same period. The blood and urine IL-17 levels between the two groups were compared and analyzed. Results: A total of 31 patients were included in the experimental group and 34 in the control group. The blood and urine IL-17 levels in the experimental group were both significantly higher than those in the control group ( < 0.05 for both). Additionally, a higher difference in IL-17 levels was observed in serum compared to urine samples. Conclusion: Interleukin-17 is an effective immunomarker for predicting the occurrence and progression of bladder cancer.

Keywords: Interleukin-17; Bladder cancer; Biomarker; Disease progression

正文内容 / Content：

可下载并阅读全文PDF，请按照本文版权许可使用。

Download the full text PDF for viewing and using it according to the license of this paper.

参考文献 / References：

Dobruch J, Oszczudowski M. Bladder Cancer: Current Challenges and Future Directions[J]. Medicina (Kaunas, Lithuania), 2021(8). DOI:10.3390/MEDICINA57080749.
Chang S S, Bochner B H, Chou R, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline[J]. Journal of Urology, 2017:S0022534717578362. DOI:10.1016/j.juro.2017.04.086.
Patel V G, Oh W K, Galsky M D. Treatment of muscle‐invasive and advanced bladder cancer in 2020[J]. CA: A Cancer Journal for Clinicians, 2020. DOI:10.3322/caac.21631.
Meyer A, Parmar P J, Shahrara S. Significance of IL-7 and IL-7R in RA and autoimmunity[J]. Autoimmunity reviews, 2022, 21(7):103120. DOI:10.1016/j.autrev.2022.103120.
Costantino N, Brembilla, Luisa, et al. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond[J]. Frontiers in immunology, 2018. DOI:10.3389/fimmu.2018.01682.
Fattahi S, Karimi M, Ghatreh-Samani M, et al. Correlation between aryl hydrocarbon receptor and IL-17+ and Foxp3+ T-cell infiltration in bladder cancer[J]. International Journal of Experimental Pathology, 2021, 102(6):249-259.
Guallar-Garrido S, Campo-Pérez V, PÉREZ-TRUJILLO M, et al. Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment[J]. Oncoimmunology, 2022, 11(1): 2051845. DOI: 10.1080/2162402X.2022.2051845.
Fattahi S, Karimi M, Ghatreh-Samani M, et al. Correlation between aryl hydrocarbon receptor and IL-17+ and Foxp3+ T-cell infiltration in bladder cancer[J]. International Journal of Experimental Pathology, 2021, 102(6):249-259.
Rasoul B, Ahmadi V A, Ali D, et al. Reduced Interleukin-17 and Transforming Growth Factor Beta Levels in Peripheral Blood as Indicators for Following the Course of Bladder Cancer[J]. Immune Network, 2014, 14(3):156-163. DOI:10.4110/in.2014.14.3.156.
De Angulo A, Faris R, Daniel B, et al. Age-related increase in IL-17 activates pro-inflammatory signaling in prostate cells[J]. The Prostate, 2015, 75(5):449-62.
Huang C C, Wang C H, Fu C H, et al. Association between cigarette smoking and interleukin-17A expression in nasal tissues of patients with chronic rhinosinusitis and asthma[J]. Medicine, 2016, 95(47):e5432. DOI:10.1097/MD.0000000000005432.